...
首页> 外文期刊>Oncogene >Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer
【24h】

Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer

机译:AKT1缺乏延迟甲状腺癌小鼠模型中的肿瘤进展,血管侵袭和远处转移

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Akt activation is common in progressive thyroid cancer. In breast cancer, Akt1 induces primary cancer growth, but is reported to inhibit metastasis in vivo in several model systems. In contrast, clinical and in vitro studies suggest a metastasis-promoting role for Akt1 in thyroid cancer. The goal of this study was to determine the functional role of Akt1 in thyroid cancer growth and metastatic progression in vivo using thyroid hormone receptor (TR) 尾~(PV/PV) knock-in (PV) mice, which develop metastatic thyroid cancer. We crossed Akt1~(鈭?鈭?/sup> and PV mice and compared tumor development, local progression, metastasis and histology in TR尾 ~(PV/PV )/Akt1 ~(+/+) (PVPV-Akt1WT) and TR尾 ~(PV/PV )/Akt1 ~(鈭?鈭?/sup> (PVPV-Akt1KO) mice. Mice were killed at 3, 6, 9, 12 and 15 months; necropsy was performed and serum thyroid stimulating hormone (TSH) was measured. Thyroid hyperplasia occurred in both groups beginning at 3 months; the thyroid size was greater in the PVPV-Akt1WT mice (P <0.001). In comparison with PVPV-Akt1WT mice, thyroid cancer development was delayed in the PVPV-Akt1KO mice (P =0.003) and the degree of tumor invasiveness was reduced. The PVPV-Akt1WT mice displayed pulmonary metastases at 12 and 15 months of age, by contrast PVPV-Akt1KO mice did not develop distant metastases at 15 months of age. Despite continued expression of Akt2 or Akt3, pAkt levels were decreased and there was evidence of reduced Akt effect on p27 in the PVPV-Akt1KO thyroids. TSH levels were similarly elevated in PV mice regardless of Akt1 expression. In conclusion, thyroid cancer development and progression in TR 尾~(PV/PV) mice are Akt1-dependent, consistent with a tumor progression-promoting role in this murine thyroid cancer model.
机译:AKT活化在进行性甲状腺癌中是常见的。在乳腺癌中,AKT1诱导原发性癌症生长,但据报道,在几种模型系统中抑制了体内的转移。相比之下,临床和在体外研究表明AKT1在甲状腺癌中的转移促进作用。本研究的目的是使用甲状腺激素受体(TR)α〜(PV / PV)敲入(PV)小鼠的甲状腺激素受体(TR)尾〜(PV)小鼠在体内测定AKT1在甲状腺癌生长和转移性进展中的功能作用。(PV)小鼠,其开发转移性甲状腺癌。我们越过AKT1〜(鈭?鈭?/ sup>和光伏小鼠,并比较肿瘤发育,局部进展,转移和组织学中 Tr〜〜( PV / PV) / akt1〜(+ / +)(PVPV-AKT1WT)和 Tr〜〜( PV / PV) / akt1〜(鈭?鈭?/ sup>(pvpv-akt1ko)小鼠。小鼠在3,6次杀死,9,12和15个月;进行尸检,测量血清甲状腺刺激激素(TSH)。从3个月开始两组发生甲状腺增生; PVPV-AKT1WT小鼠中的甲状腺尺寸更大( P < 0.001)。与PVPV-AKT1WT小鼠相比,PVPV-AKT1KO小鼠( P = 0.003)延迟甲状腺癌发育,减少了肿瘤侵犯程度。PVPV-AKT1WT小鼠在12个和12次显示肺转移15个月的年龄,通过对比度,PVPV-AKT1KO小鼠在15个月的15个月内没有发展远处转移。尽管持续表达AKT2或AKT3,但PVPV-AKT1KO甲状腺中P27的效果降低了PAKT水平。 。TSH水平相似无论akt1表达如何,ly升高。总之,Tr〜〜(PV / PV)小鼠的甲状腺癌发育和进展是Akt1依赖性,与肿瘤进展促进在该鼠甲状腺癌模型中的作用一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号